Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis (HPTN 083)
Source: View publication →
The HPTN 083 trial demonstrated that long-acting injectable cabotegravir (CAB-LA) administered every 8 weeks is superior to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV prevention in cisgender men and transgender women who have sex with men.
Key Findings
Study Design
Study Limitations
Clinical Significance
HPTN 083 revolutionized HIV prevention by providing an effective, long-acting alternative to daily oral pills, offering a vital solution for individuals who struggle with daily adherence or prefer discreet prevention methods. Its superiority results have led to the approval and global implementation of injectable PrEP as a foundational strategy for ending the HIV epidemic.
Historical Context
Prior to HPTN 083, daily oral TDF/FTC (Truvada) was the gold standard for HIV pre-exposure prophylaxis. While highly effective when taken consistently, real-world effectiveness was often limited by suboptimal adherence. HPTN 083 represented the first large-scale Phase 2b/3 trial to successfully prove that an injectable, long-acting formulation could surpass the standard of care in a head-to-head trial, moving the field toward less frequent, provider-administered dosing.
Guided Discussion
High-yield insights from every perspective
How does the mechanism of action of cabotegravir as an integrase strand transfer inhibitor (INSTI) provide a different therapeutic strategy for HIV prevention compared to the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) found in oral TDF/FTC?
Key Response
Cabotegravir inhibits the HIV integrase enzyme, preventing the viral DNA from integrating into the host cell genome, which is a later step in the viral life cycle than the reverse transcription targeted by TDF/FTC. Understanding this distinction is foundational for clinical reasoning regarding drug-class resistance and the pharmacological benefit of a long-acting formulation that ensures constant therapeutic levels without relying on daily gastrointestinal absorption.
In a patient switching from daily oral PrEP to long-acting injectable cabotegravir (CAB-LA), what is the clinical significance of the 'tail' phase, and what specific HIV testing protocol is recommended to mitigate the risk of drug resistance?
Key Response
The 'tail' refers to the period after the last injection when cabotegravir concentrations slowly decline over months. Residents must know that if a patient acquires HIV during this period, the low drug levels can select for integrase strand transfer inhibitor (INSTI) resistance. Consequently, guidelines emphasize using highly sensitive HIV-1 RNA (viral load) testing rather than just rapid antibody tests to detect breakthrough infections early.
Discuss the 'diagnostic mask' or 'LEAP' (Long-acting Early Asset Phase) phenomenon observed in HPTN 083 and its implications for the definition of PrEP 'failure' vs. 'delayed detection.'
Key Response
In HPTN 083, some participants who acquired HIV while on CAB-LA had significantly delayed antibody responses and suppressed viral loads, leading to a delay in diagnosis. Fellows must understand how this complicates the interpretation of trial data—specifically that infections might occur despite 'therapeutic' levels but remain undetectable by standard assays, potentially leading to the accumulation of resistance mutations before the infection is clinically recognized.
Given that HPTN 083 demonstrated superiority of CAB-LA over TDF/FTC, how should we weigh the clinical benefit of increased adherence against the logistical and systemic barriers of an every-8-week injection program in high-prevalence, low-resource settings?
Key Response
This question addresses the translation of trial 'efficacy' into real-world 'effectiveness.' Attendings must lead discussions on the paradigm shift from patient-managed daily pills to provider-managed injections, considering the costs of staff, cold-chain storage, and the necessity of rigorous follow-up systems to prevent 'tail' infections, which are critical teaching points for modern HIV prevention strategy.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Critique the use of the 'double-dummy' design in HPTN 083. How did the inclusion of oral placebos and sham injections affect the trial's ability to measure the true 'adherence advantage' that injectable formulations theoretically provide in a real-world setting?
Key Response
While a double-dummy design is the gold standard for maintaining blinding, it forces participants to adhere to a daily oral regimen (even if it's a placebo) to remain in the study. This potentially underestimates the real-world superiority of CAB-LA, as the 'control' group's behavior in the trial might not reflect the poor adherence seen with daily oral PrEP in clinical practice, thereby narrowing the observed gap in incidence between the two arms.
Considering the retrospective discovery of HIV infections that were present at enrollment but missed by standard screening, how does the 'integrase inhibitor-induced viral suppression' seen in HPTN 083 challenge our standard criteria for primary endpoints in PrEP trials?
Key Response
Editors look for threats to validity such as misclassification bias. If a drug suppresses viral replication so effectively that standard diagnostic assays fail to detect an infection that occurred at baseline, the drug might be incorrectly credited with 'preventing' an infection it is actually 'treating.' This forces a methodological re-evaluation of how 'incident' cases are defined and verified in future long-acting agent trials.
Based on the 66% reduction in HIV incidence reported in HPTN 083, should CAB-LA be recommended as the 'preferred' PrEP modality for cisgender MSM and transgender women, or should it remain a 'choice' alongside TDF/FTC and TAF/FTC?
Key Response
The committee must balance the 'superiority' found in the trial with the current CDC and WHO guidelines that emphasize patient choice. While HPTN 083 provides high-level evidence (Level 1A) for CAB-LA, guidelines currently emphasize that the 'best' PrEP is the one the patient can consistently access and use. The committee must decide if the risk of resistance 'tails' and higher costs justify a 'preferred' status or if it should remain one of several equivalent options depending on the patient's adherence profile.
Clinical Landscape
Noteworthy Related Trials
iPrEx Trial
Tested
Daily oral TDF/FTC
Population
MSM and transgender women
Comparator
Placebo
Endpoint
HIV acquisition
PROUD Study
Tested
Daily oral TDF/FTC
Population
MSM at high risk of HIV infection
Comparator
Delayed TDF/FTC initiation
Endpoint
HIV infection rate
HPTN 084 Trial
Tested
Long-acting injectable cabotegravir every 8 weeks
Population
Cisgender women in sub-Saharan Africa
Comparator
Daily oral TDF/FTC
Endpoint
Incident HIV infection
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis